For the 4Q FY 2012, Indoco Remedies is expected to report top-line growth of 28.7 % y o y to Rs.155 cr.
The company's OPM is expected to expand by 120bp y o y to 14.1%, driven by growth in domestic formulation sales. As a result, net profit is
expected to in crease by 31.6% y o y to Rs.16.0 cr on the back of improvement in OPM.
We maintain our Buy view on the stock with a target price of Rs.81.
By Angel Broking, 6th Floor, Ackruti Star Central Road,MIDC, Andheri (E) , Mumbai-93
Main : (91-22) 3935 7600 Extn : 6956 Website : www.angelbroking.com
The company's OPM is expected to expand by 120bp y o y to 14.1%, driven by growth in domestic formulation sales. As a result, net profit is
expected to in crease by 31.6% y o y to Rs.16.0 cr on the back of improvement in OPM.
We maintain our Buy view on the stock with a target price of Rs.81.
By Angel Broking, 6th Floor, Ackruti Star Central Road,MIDC, Andheri (E) , Mumbai-93
Main : (91-22) 3935 7600 Extn : 6956 Website : www.angelbroking.com
No comments:
Post a Comment